Background
==========

Hepatocellular carcinoma (HCC) is one of the most lethal human malignancies in China. A report on the global surveillance of cancer survival trends showed that HCC accounts for 12.5% of the 18 most prevalent cancers and that the 5-year survival rate after HCC diagnosis is less than 15% in China \[[@b1-medscimonit-25-2079]\]. Many strategies have been explored to treat HCC in the past, including surgical resection, radiotherapy, chemotherapy, and biotherapy. However, improvements in HCC prognosis have been limited \[[@b2-medscimonit-25-2079]\]. The molecular carcinogenesis of HCC remains unclear and it is widely accepted that alterations in gene expression can lead to the abnormal proliferation of cancer cells. Therefore, novel molecules need to be identified to better diagnose and treat HCC.

In recent years, long noncoding RNAs (lncRNAs) have been identified and have been shown to participate in numerous signalling pathways as auxiliary regulators of proteins. lncRNAs have been shown to target several chromatin modification complexes involved in gene regulation \[[@b3-medscimonit-25-2079]\]. In addition, several other studies have demonstrated that active chromatin states are associated with lncRNAs \[[@b4-medscimonit-25-2079]\]. The associations between lncRNAs and gene regulation in HCC have been widely studied, and many lncRNAs, such as UFC1 and PVT1, have been used to predict HCC outcome. Mechanistically, these lncRNAs can directly sponge microRNAs or interact with mRNA stabilizing proteins to disrupt gene regulation \[[@b5-medscimonit-25-2079],[@b6-medscimonit-25-2079]\].

lncRNA SNHG16, located at chromosome 17q25.1, was originally identified as an oncogene in neuroblastoma \[[@b7-medscimonit-25-2079]\]. Ectopic expression of SNHG16 has been shown to induce transformation of NIH3T3 cells, while knockdown of endogenous SNHG16 significantly inhibits cell growth \[[@b7-medscimonit-25-2079]\]. Recently, several studies investigated the oncogenic effects of SNHG16 in a variety of tumors, such as acute lymphoblastic leukaemia, non-small cell lung cancer, and hemangioma \[[@b8-medscimonit-25-2079]--[@b10-medscimonit-25-2079]\]. In addition, lncRNA SNHG16 is also involved in the LPS-induced inflammatory pathway via the regulation of miR-15a/16 \[[@b11-medscimonit-25-2079]\]. However, the relationship between HCC prognosis and lncRNA SNHG16 remains unclear.

In this study, we analysed the clinicopathologic and prognostic significance of lncRNA SNHG16 in HCC patients. We also downregulated the expression of lncRNA SNHG16 in 2 HCC cell lines to detect its function *in vitro*. Our results indicated that lncRNA SNHG16 expression could potentially be used for HCC prognosis in the future.

Material and Methods
====================

Patients and specimens
----------------------

In this study, 2 independent cohorts were enrolled. In cohort 1, fresh HCC tissues and adjacent non-cancerous samples were collected from 10 patients who had been pathologically diagnosed with HCC and undergone a hepatectomy between April 2016 and December 2016 at the First Affiliated Hospital of the Anhui Medical University (Hefei, China). In cohort 2, formalin-fixed, paraffin-embedded samples from 61 HCC patients who underwent initial surgical resection between February 2008 to December 2012 were collected randomly from the Department of Pathology at the First Affiliated Hospital of the Anhui Medical University. Informed consent was obtained from all patients and the study was approved by the Biomedical Ethics Committee of Anhui Medical University. Pathological staging was performed according to the international staging system \[[@b12-medscimonit-25-2079]\].

*In situ* hybridization (ISH) staining
--------------------------------------

ISH was performed according to the manufacturer's protocol (ISH kit, Boster Bio-Engineering Company, Wuhan, China). ISH staining was scored by 2 independent pathologists as negative (−), weakly positive (+), or strongly positive (++).

Follow-up
---------

In cohort 2, each patient was scheduled for an examination every 3 months for the first 2 years and at 6-month intervals thereafter during the follow-up period (5 years). Testing included blood analysis, ultrasound examination, and computed tomography.

Cell culture and transfection
-----------------------------

One normal liver cell line (HL-7702) and 4 classic HCC cell lines (SK-Hep-1, Huh7, Hep3B, and HepG2) were purchased from the Cell Bank of the Type Culture Collection (Chinese Academy of Sciences, Shanghai, China) and maintained in Dulbecco's modified Eagle's medium (DMEM) (Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (Gibco), 2 mmol/l L-glutamine (HyClone, Logan, UT), and penicillin (50 U/ml)/streptomycin (50 μg/ml) (HyClone) at 37°C in a 5% CO~2~ humidified chamber.

RNA interference
----------------

The siRNA of human SNHG16 and a scrambled negative control siRNA were purchased from Genepharma (Shanghai, China). Transfection was performed using Lipofectamine RNAiMAX reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions.

Quantitative RT-PCR
-------------------

Total RNA from the cell lines and fresh tissues was extracted with TRIzol reagent (Invitrogen) according to the manufacture's protocol. Next, 2 μg of total RNA was reverse transcribed using a First Strand cDNA kit (Invitrogen) to synthesize the cDNA template. qRT-PCR was performed on a 7500 Fast Real-Time PCR system (Applied Biosystem, Rotkreuz, Switzerland) using a SYBR Green PCR kit (Takara, Dalian, China). The primer sequences were as follows:

1.  SNHG16 F: 5′-GCAGAATGCCATGGTTTCCC-3′;

2.  R: 5′-GGACAGCTGGCAAGAGACTT-3′

Cell viability assay
--------------------

Cell viability assays were performed using the Cell Counting Kit-8 (CCK-8, Dojindo, Japan) according to the manufacturer's protocol. For treatment with SNHG16 siRNA and the scrambled negative control, cells were plated 48 h after transfection and incubated for 1--3 days. In the sorafenib resistance assay, transfected cells were treated with sorafenib (dose range, 0--32 μM) for 72 h, and then cell inhibition was measured using the CCK-8 assay.

Cell migration and invasion assay
---------------------------------

Cell migration and invasion assays were performed in Transwell chambers (Corning Costar, Cambridge, MA), with the cell invasion assays carried out in a chamber that contained a Matrigel (BD Biosciences, San Jose, CA)-precoated membrane. HepG2 cells were transfected with SNHG16 siRNA or a scrambled negative control siRNA and were then serum-starved for 24 h before conducting the assays. For the migration assay, 1×10^5^ cells were plated into the top chamber of a Transwell device (Corning Costar) with 0.1% bovine serum albumin (BSA). For the invasion assay, cells were plated on filters coated with 20 μg/cm^2^ of reconstituted Matrigel basement membranes. The bottom chamber was filled with complete medium. After incubation at 37°C for 24 h, the cells that had not migrated or invaded from the upper membrane surface were removed using cotton swabs. Cells adhered on the lower membrane surface of the filters were fixed in 100% methanol and stained with 0.5% crystal violet at room temperature. Cell numbers were quantitated by counting the cells in 5 random fields (original magnification, ×200).

Statistical analysis
--------------------

The chi-squared test was used to examine the association between lncRNA SNHG16 expression and various patient clinicopathologic factors. Survival time comparisons are shown using Kaplan-Meier curves, and significant differences were compared with a log-rank test. Prognostic value was determined by multivariate Cox regression analysis. P values \<0.05 were considered statistically significant. All statistical analyses were performed using SPSS 19.0 software (Abbott Laboratories, North Chicago, IL).

Results
=======

SNHG16 is upregulated in HCC tissues and cell lines
---------------------------------------------------

We investigated SNHG16 expression in HCC tissues and cell lines. The expression of SNHG16 was detected in 10 paired HCC samples and adjacent non-cancerous tissues by qRT-PCR (Cohort 1). SNHG16 expression levels were significantly upregulated in cancerous tissues compared to non-tumor tissues (*P*=0.033, [Figure 1A](#f1-medscimonit-25-2079){ref-type="fig"}). Furthermore, all 4 HCC cell lines (SK-Hep-1, Huh7, Hep3B, and HepG2) expressed higher levels of SNHG16 compared to the normal hepatocyte cell line HL-7702 ([Figure 1B](#f1-medscimonit-25-2079){ref-type="fig"}). To further validate its dysregulated expression, we investigated the levels of SNHG16 in an additional 61 paired paraffin-embedded samples by ISH (Cohort 2). Samples with negative or weakly positive SNHG16 levels were defined as having low expression, while strongly positive samples were defined as having high expression, and 35 out of 61 (57.4%) cases exhibited high expression of SNHG16 ([Figure 1C](#f1-medscimonit-25-2079){ref-type="fig"}). Together, these results indicate that SNHG16 is upregulated in HCC.

Correlation between SNHG16 and clinicopathologic factors in patients with HCC
-----------------------------------------------------------------------------

To investigate whether SNHG16 is associated with HCC progression, we analysed the correlation between SNHG16 expression and clinicopathologic parameters in 61 HCC patients (Cohort 2). As shown in [Table 1](#t1-medscimonit-25-2079){ref-type="table"}, statistical analysis revealed a positive correlation between SNHG16 expression and tumor size (*P*=0.031), AFP level (*P*\<0.001), portal vein tumor thrombus (PVTT) (*P*=0.007), and metastasis (*P*=0.007). However, no statistically significant correlations were found between SNGH16 and age, sex, pathologic grade, and liver cirrhosis (*P*\>0.05).

SNHG16 expression is associated with poor survival of HCC patients
------------------------------------------------------------------

To investigate the relationship between SNGH16 and HCC patient prognosis, Kaplan-Meier analysis and log-rank tests were performed to evaluate the association between SNHG16 expression and overall survival (OS) or disease-free survival (DFS) of HCC patients. The results indicated that patients with higher SNHG16 expression have worse DFS (*P*\<0.001) and OS (*P*\<0.001) compared to patients with lower SNHG16 expression ([Figure 2](#f2-medscimonit-25-2079){ref-type="fig"}). To further evaluate whether the level of SNHG16 could be identified as a prognostic factor for HCC patients, univariate and multivariate analysis was performed. Univariate analysis demonstrated that tumor size (*P*\<0.001), AFP level (*P*\<0.001*),* PVTT (*P*\<0.001), metastasis (*P*\<0.001), and SNHG16 expression (*P*\<0.001) were significantly correlated with OS in HCC patients ([Table 2](#t2-medscimonit-25-2079){ref-type="table"}). Multivariate analysis indicated that SNHG16 expression (HR=4.985, 95% CI=1.451--17.132, *P*=0.011), AFP level (HR=7.078, 95% CI=2.465--20.326, *P*\<0.001), PVTT (HR=12.082, 95% CI=3.660--39.890, P\<0.001) and metastasis (HR=6.179, 95% CI=2.188--17.444, *P*=0.001) were significant independent predictors for patients with HCC ([Table 2](#t2-medscimonit-25-2079){ref-type="table"}).

Knockdown of SNHG16 inhibits proliferation, migration, and invasion and reverses sorafenib resistance in HCC cells
------------------------------------------------------------------------------------------------------------------

Subsequently, to investigate the biological role of SNHG16 in HCC progression and therapy resistance, we used siRNA to downregulate the expression of SNHG16 in Hep3B and HepG2 cell lines. As shown in [Figure 3A](#f3-medscimonit-25-2079){ref-type="fig"}, the expression of SNHG16 was effectively silenced using siRNA (P\<0.01). The CCK-8 assay indicated that SNHG16 knockdown significantly decreased cellular proliferation in Hep3B and HepG2 cell lines ([Figure 3B](#f3-medscimonit-25-2079){ref-type="fig"}). In addition, knockdown of SNHG16 expression reduced the migration and invasion ability of HCC cells ([Figure 3C](#f3-medscimonit-25-2079){ref-type="fig"}). Moreover, the sorafenib resistance assay indicated that knockdown of SNHG16 expression significantly reverses sorafenib resistance in both Hep3B and HepG2 cell lines ([Figure 3D](#f3-medscimonit-25-2079){ref-type="fig"}). Collectively, these data show that knockdown of SNHG16 expression significantly inhibits proliferation, migration, invasion, and sorafenib resistance in HCC cells.

Discussion
==========

In this study, we detected the expression of SNHG16 in HCC tissues and cell lines and then analysed the prognostic value of SNHG16 in patients with HCC. Our results revealed that SNHG16 is upregulated in HCC tissues and cell lines. The SNHG16 expression level was correlated with tumor size, AFP level, PVTT, and metastasis. Further statistical analysis indicated that high expression of SNHG16 is associated with worse prognosis in HCC patients. Multivariate analysis indicated that SNHG16 could be an independent prognosticator for HCC patients. Furthermore, suppression of SNHG16 significantly inhibited proliferation, migration, invasion, and sorafenib resistance in HCC cells *in vitro*. Collectively, our results show that SNHG16 may play an important role in the development and progression of HCC.

It is well established that lncRNAs play crucial roles in a large variety of cellular processes and that dysregulated lncRNA expression is probably pervasive in human cancers \[[@b13-medscimonit-25-2079]\]. For example, one of the most well-studied lncRNAs, HOTAIR, promotes cancer metastasis by reprograming the chromatin state \[[@b14-medscimonit-25-2079]\]. HULC is upregulated in HCC tissues compared to adjacent non-cancerous tissues, and ectopic expression of HULC facilitates HCC progression by promoting cell viability, invasion, and vascularization \[[@b15-medscimonit-25-2079],[@b16-medscimonit-25-2079]\].

Recently, accumulating evidence demonstrated that lncRNAs can serve as biomarkers and prognosticators for many cancers, including HCC \[[@b17-medscimonit-25-2079],[@b18-medscimonit-25-2079]\]. For example, overexpression of UFC1 is correlated with tumor size, clinical stage, and patient outcomes \[[@b5-medscimonit-25-2079]\]. These data indicate that lncRNAs may play crucial roles in HCC carcinogenesis and progression. In this study, we demonstrated that SNHG16 is upregulated in HCC and that it correlates with a worse prognosis in HCC patients. Importantly, SNHG16 has been reported to be a potential oncogene in several carcinomas, including bladder \[[@b19-medscimonit-25-2079]\], breast \[[@b20-medscimonit-25-2079]\], neuroblastoma \[[@b7-medscimonit-25-2079]\], and non-small cell lung cancer \[[@b9-medscimonit-25-2079]\], which is in line with results of the present study. In breast cancer, SNHG16 is highly expressed and promotes cell growth and invasiveness by sponging miR-98 \[[@b20-medscimonit-25-2079]\]. A similar analysis also reported that SNHG16 overexpression predicted poor survival in patients with esophageal squamous cell carcinoma \[[@b21-medscimonit-25-2079]\]. However, the underlying mechanisms by which SNHG16 promotes cancer progression, including in HCC, remain largely unknown. Numerous studies have demonstrated that lncRNA regulatory mechanisms strongly depend on the location of the lncRNA \[[@b22-medscimonit-25-2079]\]. lncRNAs located in the cytoplasm may serve as partners with miRNA, mRNA, or proteins to regulate target genes in a post-transcriptional pathway \[[@b23-medscimonit-25-2079]\]. In the present study, ISH indicated that SNHG16 is located in the cytoplasm ([Figure 1C](#f1-medscimonit-25-2079){ref-type="fig"}), where it may function as a sponge for miRNAs or integrate with proteins to regulate downstream molecules. The detailed mechanisms of SNHG16 in HCC progression and sorafenib resistance will be investigated in the future.

Conclusions
===========

In summary, our results revealed significant associations between SNHG16 expression and various clinicopathologic characteristics and prognosis in patients with HCC. Moreover, survival analysis showed that the lncRNA SNHG16 is an independent prognostic factor for DFS and OS in HCC. These findings suggest that SNHG16 could be used as a pathological marker to identify individuals with poor outcomes and providing a reference for clinical therapy in the future.
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![SNHG16 overexpression in HCC tissues and cell lines. (**A**) Analysis of SNHG16 level in 10 paired HCC samples and adjacent non-cancerous tissues by qRT-PCR (Cohort 1). (**B**) Analysis of SNHG16 in HCC cell lines and a normal hepatocyte cell line HL-7702. (**C**) Analysis of SNHG16 expression in HCC tissues by ISH assays (Cohort 2).](medscimonit-25-2079-g001){#f1-medscimonit-25-2079}

![Kaplan-Meier curves of (**A**) DFS and (**B**) OS according to the level of lncRNA SNHG16 expression.](medscimonit-25-2079-g002){#f2-medscimonit-25-2079}

![Knockdown of SNHG16 inhibits proliferation, migration, and invasion and reverses sorafenib resistance in HCC cells. (**A**) Hep3B and HepG2 cells were transfected with SNHG16 siRNA or a scrambled negative control. The transfection efficiency was detected by qRT-PCR. \*\* *P*\<0.01. (**B**) Hep3B and HepG2 cells were transfected with SNHG16 siRNA or a scrambled negative control. Cell growth was detected at days 1--3 after transfection. The data are presented as the mean ±SD. \*\* *P*\<0.01. (**C**) HepG2 cells were transfected with SNHG16 siRNA or a scrambled negative control. Cell migration and invasion abilities were analysed by Transwell migration assay (above) and invasion assay (below) (magnification: ×200). \*\* *P*\<0.01. (**D**) Hep3B and HepG2 cells were transfected with SNHG16 siRNA or a scrambled negative control. The sensitivity to sorafenib was detected by CCK-8 assay.](medscimonit-25-2079-g003){#f3-medscimonit-25-2079}

###### 

Correlation between SNHG16 expression and HCC clinicopathologic features.

  Characteristic      SNHG16 expression level   P-value      
  ------------------- ------------------------- ------------ -------------
  Age                                                        0.149
   ≤55                16 (61.5%)                15 (42.9%)   
   \>55               10 (38.5%)                20 (57.1%)   
  Sex                                                        0.186
   Male               16 (61.5%)                27 (77.1%)   
   Female             10 (38.5%)                8 (22.9)     
  Tumor size (cm)                                            **0.031**
   ≤5                 21 (80.8%)                19 (54.3%)   
   \>5                5 (19.2%)                 16 (45.7%)   
  Pathologic grade                                           0.096
   I--II              16 (61.5%)                14 (40.0%)   
   III--IV            10 (38.5%)                21 (60.0%)   
  AFP level (ng/ml)                                          **\<0.001**
   ≤500               23 (88.5%)                15 (42.9%)   
   \>500              3 (11.5%)                 20 (57.1%)   
  Liver cirrhosis                                            0.856
   With               15 (57.7%)                21 (60.0%)   
   Without            11 (42.3%)                14 (40.0%)   
  PVTT                                                       **0.007**
   No                 25 (96.2%)                24 (68.6%)   
   Yes                1 (3.8%)                  11 (31.4%)   
  Metastasis                                                 **0.007**
   No                 25 (96.2%)                24 (68.6%)   
   Yes                1 (3.8%)                  11 (31.4%)   

PTVV -- portal vein tumor thrombus.

###### 

Univariate and multivariate analysis of OS by Cox regression analysis.

  Variables          Univariate analysis      Multivariate analysis                            
  ------------------ ------------------------ ----------------------- ------------------------ -------------
  Age                1.809 (0.863--3.796)     0.117                                            
  Sex                0.845 (0.374--1.909)     0.685                                            
  Tumor size         4.871 (2.300--10.320)    **\<0.001**                                      
  Pathologic grade   1.013 (0.489--2.099)     0.973                                            
  AFP level          13.411 (5.170--34.786)   **\<0.001**             7.078 (2.465--20.326)    **\<0.001**
  Liver cirrhosis    1.059 (0.505--2.219)     0.880                                            
  PVTT               10.133 (4.132--24.848)   **\<0.001**             12.082 (3.660--39.890)   **\<0.001**
  Metastasis         8.468 (3.768--19.028)    **\<0.001**             6.179 (2.188--17.444)    **0.001**
  SNHG16             10.238 (3.493--30.007)   **\<0.001**             4.985 (1.451--17.132)    **0.011**

PTVV -- portal vein tumor thrombus.
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